Top

Published in:

01-11-2020 | Metastasis | Original Article

Infiltration of T cells promotes the metastasis of ovarian cancer cells via the modulation of metastasis-related genes and PD-L1 expression

Authors: Jing-Jing Wang, Michelle Kwan-Yee Siu, Yu-Xin Jiang, David Wai Chan, Annie Nga-Yin Cheung, Hextan Yuen-Sheung Ngan, Karen Kar-Loen Chan

Published in: Cancer Immunology, Immunotherapy | Issue 11/2020

Abstract

Due to its high ability to disseminate, ovarian cancer remains one of the largest threats to women’s health, worldwide. Evidence showed that the immune cells infiltrating the tumor microenvironment are crucial in mediating metastasis. Therefore, it is necessary to understand which types of immune cells are involved in metastasis, and to determine the mechanisms by which they influence the process. By immunohistochemistry, we found that higher concentrations of intratumoral CD8⁺ T cells were found to be correlated with an advanced grade and stage of ovarian cancer. Additionally, the infiltration of stromal CD8⁺ T cells was also significantly higher in tissues with advanced stages and metastatic tumors. A positive correlation between the infiltration of FoxP3⁺ Treg cells and histological grade was also observed, regardless of location. PD-L1 expression in metastatic tumors was also higher than that in paired primary ovarian tumors. Transwell migration and invasion assays revealed the increased migration and invasion of ovarian cancer cell lines (A2780CP and ES2) and ascites-derived ovarian cancer cells following co-culturing with CD8⁺ T cells. Enhanced expression of MMP-9, uPA, VEGF, bFGF, IL-8, IL-10, and PD-L1 by cancer cells following co-culturing with CD8⁺ T cells were also detected by qPCR, ELISA or flow cytometry. In conclusion, our findings suggest that the infiltrated T cells could promote the development of ovarian cancer, and provide another mechanism of immune evasion mediated by T cells.

American Cancer Society (2011) Cancer Facts & Figures 2011. Atlanta: American Cancer Society

Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A, Siegel RL (2018) Ovarian cancer statistics. CA Cancer J Clin 68(4):284–296. https://doi.org/10.3322/caac.21456CrossRefPubMedPubMedCentral

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674. https://doi.org/10.1016/j.cell.2011.02.013CrossRefPubMed

Kulbe H, Chakravarty P, Leinster DA, Charles KA, Kwong J, Thompson RG, Coward JI, Schioppa T, Robinson SC, Gallagher WM, Galletta L, Australian Ovarian Cancer Study G, Salako MA, Smyth JF, Hagemann T, Brennan DJ, Bowtell DD, Balkwill FR (2012) A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Can Res 72(1):66–75. https://doi.org/10.1158/0008-5472.CAN-11-2178CrossRef

Reinartz S, Schumann T, Finkernagel F, Wortmann A, Jansen JM, Meissner W, Krause M, Schworer AM, Wagner U, Muller-Brusselbach S, Muller R (2014) Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse. Int J Cancer J Int Du Cancer 134(1):32–42. https://doi.org/10.1002/ijc.28335CrossRef

Condeelis J, Pollard JW (2006) Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124(2):263–266. https://doi.org/10.1016/j.cell.2006.01.007CrossRefPubMed

Drakes ML, Stiff PJ (2018) Regulation of ovarian cancer prognosis by immune cells in the tumor microenvironment. Cancers (Basel). https://doi.org/10.3390/cancers10090302CrossRef

Casares N, Arribillaga L, Sarobe P, Dotor J, Lopez-Diaz de Cerio A, Melero I, Prieto J, Borras-Cuesta F, Lasarte JJ (2003) CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol 171(11):5931–5939CrossRefPubMed

Maloy KJ, Powrie F (2001) Regulatory T cells in the control of immune pathology. Nat Immunol 2(9):816–822. https://doi.org/10.1038/ni0901-816CrossRefPubMed

10.

Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, Kepner J, Odunsi T, Ritter G, Lele S, Chen YT, Ohtani H, Old LJ, Odunsi K (2005) Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 102(51):18538–18543. https://doi.org/10.1073/pnas.0509182102CrossRefPubMedPubMedCentral

11.

Wolf D, Wolf AM, Rumpold H, Fiegl H, Zeimet AG, Muller-Holzner E, Deibl M, Gastl G, Gunsilius E, Marth C (2005) The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 11(23):8326–8331. https://doi.org/10.1158/1078-0432.CCR-05-1244CrossRefPubMed

12.

Shepherd TG, Theriault BL, Campbell EJ (2007) Nachtigal MW (2015) Primary culture of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from patients (vol 1, pg 2643, 2007). Nat Protoc 10(9):1457–1457. https://doi.org/10.1038/nprot0915-1457bCrossRef

13.

Wang J-J, Siu MK, Jiang Y-X, Leung TH, Chan DW, Cheng R-R, Cheung AN, Ngan HY, Chan KK (2019) Aberrant upregulation of PDK1 in ovarian cancer cells impairs CD8+ T cell function and survival through elevation of PD-L1. OncoImmunology 8(11):1659092. https://doi.org/10.1080/2162402X.2019.1659092CrossRef

14.

Shi J, Wei PK (2015) Low-dose interleukin-8 induces the adhesion, migration and invasion of the gastric cancer SGC-7901 cell line. Oncol Lett 10(5):2871–2877. https://doi.org/10.3892/ol.2015.3641CrossRefPubMedPubMedCentral

15.

Mustea A, Konsgen D, Braicu EI, Pirvulescu C, Sun P, Sofroni D, Lichtenegger W, Sehouli J (2006) Expression of IL-10 in patients with ovarian carcinoma. Anticancer Res 26(2C):1715–1718PubMed

16.

Lane D, Matte I, Garde-Granger P, Bessette P, Piche A (2018) Ascites IL-10 promotes ovarian cancer cell migration. Cancer Microenviron 11(2–3):115–124. https://doi.org/10.1007/s12307-018-0215-3CrossRefPubMedPubMedCentral

17.

Pietzner K, Nasser S, Alavi S, Darb-Esfahani S, Passler M, Muallem MZ, Sehouli J (2018) Checkpoint-inhibition in ovarian cancer: rising star or just a dream? J Gynecol Oncol 29(6):e93. https://doi.org/10.3802/jgo.2018.29.e93CrossRefPubMedPubMedCentral

18.

Wang S, Li J, Xie J, Liu F, Duan Y, Wu Y, Huang S, He X, Wang Z, Wu X (2018) Programmed death ligand 1 promotes lymph node metastasis and glucose metabolism in cervical cancer by activating integrin beta4/SNAI1/SIRT3 signaling pathway. Oncogene 37(30):4164–4180. https://doi.org/10.1038/s41388-018-0252-xCrossRefPubMed

19.

Li J, Chen L, Xiong Y, Zheng X, Xie Q, Zhou Q, Shi L, Wu C, Jiang J, Wang H (2017) Knockdown of PD-L1 in human gastric cancer cells inhibits tumor progression and improves the cytotoxic sensitivity to CIK therapy. Cell Physiol Biochem 41(3):907–920. https://doi.org/10.1159/000460504CrossRefPubMed

20.

Yahata T, Mizoguchi M, Kimura A, Orimo T, Toujima S, Kuninaka Y, Nosaka M, Ishida Y, Sasaki I, Fukuda-Ohta Y, Hemmi H, Iwahashi N, Noguchi T, Kaisho T, Kondo T, Ino K (2019) Programmed cell death ligand 1 disruption by clustered regularly interspaced short palindromic repeats/Cas9-genome editing promotes antitumor immunity and suppresses ovarian cancer progression. Cancer Sci 110(4):1279–1292. https://doi.org/10.1111/cas.13958CrossRefPubMedPubMedCentral

21.

Christofori G (2006) New signals from the invasive front. Nature 441(7092):444–450. https://doi.org/10.1038/nature04872CrossRefPubMed

22.

Torre LA, Islami F, Siegel RL, Ward EM, Jemal A (2017) global cancer in women: burden and trends. Cancer Epidemiol Biomarkers Prev 26(4):444–457. https://doi.org/10.1158/1055-9965.EPI-16-0858CrossRefPubMed

23.

Moffitt L, Karimnia N, Stephens A, Bilandzic M (2019) Therapeutic targeting of collective invasion in ovarian cancer. Int J Mol Sci. https://doi.org/10.3390/ijms20061466CrossRefPubMedPubMedCentral

24.

Yasukawa M, Liu Y, Hu L, Cogdell D, Gharpure KM, Pradeep S, Nagaraja AS, Sood AK, Zhang W (2017) ADAMTS16 mutations sensitize ovarian cancer cells to platinum-based chemotherapy. Oncotarget 8(51):88410–88420. https://doi.org/10.18632/oncotarget.11120CrossRefPubMed

25.

Blomberg OS, Spagnuolo L, de Visser KE (2018) Immune regulation of metastasis: mechanistic insights and therapeutic opportunities. Dis Model Mech. https://doi.org/10.1242/dmm.036236CrossRefPubMedPubMedCentral

26.

Yaguchi T, Sumimoto H, Kudo-Saito C, Tsukamoto N, Ueda R, Iwata-Kajihara T, Nishio H, Kawamura N, Kawakami Y (2011) The mechanisms of cancer immunoescape and development of overcoming strategies. Int J Hematol 93(3):294–300. https://doi.org/10.1007/s12185-011-0799-6CrossRefPubMed

27.

Meng Y, Liang H, Hu J, Liu S, Hao X, Wong MSK, Li X, Hu L (2018) PD-L1 expression correlates with tumor infiltrating lymphocytes and response to neoadjuvant chemotherapy in cervical cancer. J Cancer 9(16):2938–2945. https://doi.org/10.7150/jca.22532CrossRefPubMedPubMedCentral

28.

Cai Z, Yang F, Yu L, Yu Z, Jiang L, Wang Q, Yang Y, Wang L, Cao X, Wang J (2012) Activated T cell exosomes promote tumor invasion via Fas signaling pathway. J Immunol 188(12):5954–5961. https://doi.org/10.4049/jimmunol.1103466CrossRefPubMed

29.

Nyberg P, Xie L, Kalluri R (2005) Endogenous inhibitors of angiogenesis. Can Res 65(10):3967–3979. https://doi.org/10.1158/0008-5472.CAN-04-2427CrossRef

30.

Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362(6423):841–844. https://doi.org/10.1038/362841a0CrossRefPubMed

31.

Guo H, Zhu Q, Yu X, Merugu SB, Mangukiya HB, Smith N, Li Z, Zhang B, Negi H, Rong R, Cheng K, Wu Z, Li D (2017) Tumor-secreted anterior gradient-2 binds to VEGF and FGF2 and enhances their activities by promoting their homodimerization. Oncogene 36(36):5098–5109. https://doi.org/10.1038/onc.2017.132CrossRefPubMed

32.

Khochenkov DA, Solomko ES, Peretolchina NM, Ryabaya OO, Stepanova EV (2015) Antiangiogenic activity of alofanib, an allosteric inhibitor of fibroblast growth factor receptor 2. Bull Exp Biol Med 160(1):84–87. https://doi.org/10.1007/s10517-015-3104-5CrossRefPubMed

33.

Zamarron BF, Chen W (2011) Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci 7(5):651–658CrossRefPubMedPubMedCentral

34.

Waugh DJ, Wilson C (2008) The interleukin-8 pathway in cancer. Clin Cancer Res 14(21):6735–6741. https://doi.org/10.1158/1078-0432.CCR-07-4843CrossRefPubMed

35.

Inoue K, Slaton JW, Eve BY, Kim SJ, Perrotte P, Balbay MD, Yano S, Bar-Eli M, Radinsky R, Pettaway CA, Dinney CP (2000) Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res 6(5):2104–2119PubMed

36.

Zhou J, Ye F, Chen H, Lv W, Gan N (2007) The expression of interleukin-10 in patients with primary ovarian epithelial carcinoma and in ovarian carcinoma cell lines. J Int Med Res 35(3):290–300. https://doi.org/10.1177/147323000703500302CrossRefPubMed

37.

Sheikhpour E, Noorbakhsh P, Foroughi E, Farahnak S, Nasiri R, Neamatzadeh H (2018) A survey on the role of interleukin-10 in breast cancer: a narrative. Rep Biochem Mol Biol 7(1):30–37PubMedPubMedCentral

38.

Kim S, Lee J, Jeon M, Lee JE, Nam SJ (2016) MEK-dependent IL-8 induction regulates the invasiveness of triple-negative breast cancer cells. Tumour Biol 37(4):4991–4999. https://doi.org/10.1007/s13277-015-4345-7CrossRefPubMed

39.

Qiu XY, Hu DX, Chen WQ, Chen RQ, Qian SR, Li CY, Li YJ, Xiong XX, Liu D, Pan F, Yu SB (1864) Chen XQ (2018) PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation. Biochim Biophys Acta Mol Basis Dis 5:1754–1769. https://doi.org/10.1016/j.bbadis.2018.03.002CrossRef

40.

Wang Y, Wang H, Zhao Q, Xia Y, Hu X, Guo J (2015) PD-L1 induces epithelial-to-mesenchymal transition via activating SREBP-1c in renal cell carcinoma. Med Oncol 32(8):212. https://doi.org/10.1007/s12032-015-0655-2CrossRefPubMed

41.

Liao Y, Chen L, Feng Y, Shen J, Gao Y, Cote G, Choy E, Harmon D, Mankin H, Hornicek F, Duan Z (2017) Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells. Oncotarget 8(18):30276–30287. https://doi.org/10.18632/oncotarget.16326CrossRefPubMedPubMedCentral

42.

Qu QX, Xie F, Huang Q, Zhang XG (2017) Membranous and cytoplasmic expression of PD-L1 in ovarian cancer cells. Cell Physiol Biochem 43(5):1893–1906. https://doi.org/10.1159/000484109CrossRefPubMed

43.

Mailloux AW, Young MR (2010) Regulatory T-cell trafficking: from thymic development to tumor-induced immune suppression. Crit Rev Immunol 30(5):435–447CrossRefPubMedPubMedCentral

44.

Shi C, Chen Y, Chen Y, Yang Y, Bing W, Qi J (2019) CD4(+) CD25(+) regulatory T cells promote hepatocellular carcinoma invasion via TGF-beta1-induced epithelial-mesenchymal transition. Onco Targets Ther 12:279–289. https://doi.org/10.2147/OTT.S172417CrossRefPubMed

45.

Yang P, Li QJ, Feng Y, Zhang Y, Markowitz GJ, Ning S, Deng Y, Zhao J, Jiang S, Yuan Y, Wang HY, Cheng SQ, Xie D, Wang XF (2012) TGF-beta-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. Cancer Cell 22(3):291–303. https://doi.org/10.1016/j.ccr.2012.07.023CrossRefPubMedPubMedCentral

46.

Barnett JC, Bean SM, Whitaker RS, Kondoh E, Baba T, Fujii S, Marks JR, Dressman HK, Murphy SK, Berchuck A (2010) Ovarian cancer tumor infiltrating T-regulatory (T(reg)) cells are associated with a metastatic phenotype. Gynecol Oncol 116(3):556–562. https://doi.org/10.1016/j.ygyno.2009.11.020CrossRefPubMed

Title: Infiltration of T cells promotes the metastasis of ovarian cancer cells via the modulation of metastasis-related genes and PD-L1 expression
Authors: Jing-Jing Wang
Michelle Kwan-Yee Siu
Yu-Xin Jiang
David Wai Chan
Annie Nga-Yin Cheung
Hextan Yuen-Sheung Ngan
Karen Kar-Loen Chan
Publication date: 01-11-2020
Publisher: Springer Berlin Heidelberg
Keywords: Metastasis
Ovarian Cancer
Ovarian Cancer
Ascites
Published in: Cancer Immunology, Immunotherapy / Issue 11/2020
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-020-02621-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2020

Clinicopathological factors associated with tumor-infiltrating lymphocyte reactivity in breast cancer

ADRB3 expression in tumor cells is a poor prognostic factor and promotes proliferation in non-small cell lung carcinoma

IL-6-induced CD39 expression on tumor-infiltrating NK cells predicts poor prognosis in esophageal squamous cell carcinoma

Cell composition and expansion strategy can reduce the beneficial effect of AKT-inhibition on functionality of CD8+ T cells

In vitro 4-1BB stimulation promotes expansion of CD8+ tumor-infiltrating lymphocytes from various sarcoma subtypes

Influence of antigen density and immunosuppressive factors on tumor-targeted costimulation with antibody-fusion proteins and bispecific antibody-mediated T cell response

Keynote webinar | Spotlight on antibody–drug conjugates in cancer